medigraphic.com
ISSN 1405-1710 (Print)

2022, Number 3

<< Back Next >>

Rev Cent Dermatol Pascua 2022; 31 (3)

Recalcitrant atopic dermatitis treated with dupilumab: first management experience at Centro Dermatológico ''Dr. Ladislao de la Pascua'', CDMX

Álvarez-Rivero V, López-Salmerón A, Medina-Bojórquez A, Jurado-Santa CF

Language: Spanish
References: 17
Page: 84-88
PDF size: 295.26 Kb.


ABSTRACT

Introduction: atopic dermatitis (AD) is one of the most prevalent inflammatory skin diseases, which typically begins during early childhood and can persist into adulthood, is characterized by a relapsing chronic course, with flares of pruritic eczema that affect the quality of life of the patient. In patients with moderate-severe disease, the use of systemic treatments is preferred to achieve disease control. Case presentation: 33-year-old man with severe atopic dermatitis, resistant to conventional treatment, who responded successfully to treatment with dupilumab. Conclusion: this is the first management experience of an AD patient with dupilumab at Centro Dermatológico Pascua. To date, the patient is under periodic review, with adequate clearance after last dose of the biologic agent and a significant increase of the quality of life.


REFERENCES

  1. Wollenberg A, Barbarot S, Bieber T et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018; 32: 657-682.

  2. Laughter MR, Maymone MBC, Mashayekhi S et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990-2017. Br J Dermatol. 2021; 184: 304-309. doi: 10.1111/bjd.19580.

  3. Yew YW, Thyssen JP, Silverberg JI. A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. J Am Acad Dermatol. 2019; 80: 390-401. doi: 10.1016/j.jaad.2018.09.035.

  4. Ständer S. Atopic dermatitis. N Engl J Med. 2021; 384: 1136-1143. doi: 10.1056/NEJMra202391.

  5. Huet F, Faffa M-S, Poizeau F, Merhand S, Misery L, Brenaut E. Characteristics of pruritus in relation to self-assessed severity of atopic dermatitis. Acta Derm Venereol. 2019; 99: 279-283.

  6. Wollenberg A, Kinberger M, Arents B et al. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol. 2022; 36: 1409-1431.

  7. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Suppl). 1980; 92: 44-47.

  8. Wollenberg A, Barbarot S, Bieber T et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018; 32: 850-878.

  9. Simpson EL, Paller AS, Siegfried EC et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020; 156: 44-56.

  10. Griffiths C, de Bruin-Weller M, Deleuran M. Dupilumab in adults with moderate-to-severe atopic dermatitis and prior use of systemic nonsteroidal immunosuppressants: analysis of four phase 3 trials. Dermatol Ther. 2021; 11: 1357-1372.

  11. Wu JJ, Spelman L, Tan JL et al. Dupilumab maintains long-term disease control in adults with moderate-to-severe atopic dermatitis as measured by well-controlled weeks: results from the LIBERTY AD CHRONOS clinical trial. Dermatol Ther. 2021; 11: 327-330.

  12. Lázaro-Sastre M, García-Sánchez A, Gómez-Cardeñosa A et al. Dupilumab in atopic dermatitis. Food Allergy. 2019; 1-15. doi: 10.1007/s40521-01900218-x.

  13. Martínez-Cabriales SA, Kirchhof MG, Constantinescu CM. Recommendations for vaccination in children with atopic dermatitis treated with dupilumab: a consensus meeting, 2020. Am J Clin Dermatol. 2021; 22: 443-455.

  14. Postestio L, Napolitano M, Bennardo L et al. Atopic dermatitis exacerbation after Covid-19 vaccination in dupilumab-treated patients. J Eur Acad Dermatol Venereol. 2022; 36: e409-e411.

  15. Rankin BD, Georgakopoulos JR, Sachdeva M et al. Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort study. J Dermatol Treat. 2022; 33: 2692-2694.

  16. El-Qushayri AE, Mahmoud MA, Salma S. Dupilumab therapy in atopic dermatitis is safe during COVID-19 infection era: a systematic review and meta-analysis of 1611 patients. Dermatol Ther. 2022; 35: e15476.

  17. Drug interaction checker (04 de agosto 2022). Medscape. https://reference.medscape.com/drug-interactionchecker




2020     |     www.medigraphic.com